165 related articles for article (PubMed ID: 22273509)
21. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
[TBL] [Abstract][Full Text] [Related]
22. Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.
Kirkby NS; Lundberg MH; Chan MV; Vojnovic I; Solomon AB; Emerson M; Mitchell JA; Warner TD
Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15782-7. PubMed ID: 24003163
[TBL] [Abstract][Full Text] [Related]
23. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors.
Baurand A; Eckly A; Bari N; Léon C; Hechler B; Cazenave JP; Gachet C
Thromb Haemost; 2000 Sep; 84(3):484-91. PubMed ID: 11019976
[TBL] [Abstract][Full Text] [Related]
24. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
Pampuch A; Cerletti C; de Gaetano G
Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
[TBL] [Abstract][Full Text] [Related]
25. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice.
Léon C; Hechler B; Freund M; Eckly A; Vial C; Ohlmann P; Dierich A; LeMeur M; Cazenave JP; Gachet C
J Clin Invest; 1999 Dec; 104(12):1731-7. PubMed ID: 10606627
[TBL] [Abstract][Full Text] [Related]
26. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
Judge HM; Buckland RJ; Sugidachi A; Jakubowski JA; Storey RF
Platelets; 2008 Mar; 19(2):125-33. PubMed ID: 18297550
[TBL] [Abstract][Full Text] [Related]
27. Adenosine diphosphate receptors on blood platelets: potential new targets for antiplatelet therapy.
Rozalski M; Nocun M; Watala C
Acta Biochim Pol; 2005; 52(2):411-5. PubMed ID: 15912207
[TBL] [Abstract][Full Text] [Related]
28. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood.
Storey RF; Newby LJ; Heptinstall S
Platelets; 2001 Nov; 12(7):443-7. PubMed ID: 11674863
[TBL] [Abstract][Full Text] [Related]
29. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow.
Turner NA; Moake JL; McIntire LV
Blood; 2001 Dec; 98(12):3340-5. PubMed ID: 11719372
[TBL] [Abstract][Full Text] [Related]
30. Effects of P2Y(1) and P2Y(12) receptor antagonists on ADP-induced shape change of equine platelets: comparison with human platelets.
Mateos-Trigos G; Evans RJ; Heath MF
Platelets; 2002; 13(5-6):285-92. PubMed ID: 12189014
[TBL] [Abstract][Full Text] [Related]
31. Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways.
Garcia A; Kim S; Bhavaraju K; Schoenwaelder SM; Kunapuli SP
Biochem J; 2010 Jul; 429(2):369-77. PubMed ID: 20441566
[TBL] [Abstract][Full Text] [Related]
32. Uridine Triphosphate Thio Analogues Inhibit Platelet P2Y
Gündüz D; Tanislav C; Sedding D; Parahuleva M; Santoso S; Troidl C; Hamm CW; Aslam M
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146050
[TBL] [Abstract][Full Text] [Related]
33. The C6-2B glioma cell P2Y(AC) receptor is pharmacologically and molecularly identical to the platelet P2Y(12) receptor.
Jin J; Tomlinson W; Kirk IP; Kim YB; Humphries RG; Kunapuli SP
Br J Pharmacol; 2001 Jun; 133(4):521-8. PubMed ID: 11399669
[TBL] [Abstract][Full Text] [Related]
34. The relative importance of the ADP receptors, P2Y12 and P2Y1, in thrombin-induced platelet activation.
Nylander S; Mattsson C; Ramström S; Lindahl TL
Thromb Res; 2003; 111(1-2):65-73. PubMed ID: 14644082
[TBL] [Abstract][Full Text] [Related]
35. Evidence that the purinergic receptor P2Y12 potentiates platelet shape change by a Rho kinase-dependent mechanism.
Hardy AR; Hill DJ; Poole AW
Platelets; 2005 Nov; 16(7):415-29. PubMed ID: 16236603
[TBL] [Abstract][Full Text] [Related]
36. Reciprocal cross-talk between P2Y1 and P2Y12 receptors at the level of calcium signaling in human platelets.
Hardy AR; Jones ML; Mundell SJ; Poole AW
Blood; 2004 Sep; 104(6):1745-52. PubMed ID: 15187029
[TBL] [Abstract][Full Text] [Related]
37. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
[TBL] [Abstract][Full Text] [Related]
38. Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism.
Jakubowski JA; Zhou C; Egan B; Wells M; Kotob-Yahfoufi M; Sugidachi A; Dahlen JR
Platelets; 2011; 22(8):619-25. PubMed ID: 21639823
[TBL] [Abstract][Full Text] [Related]
39. Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation in whole blood to assess P2Y(12) inhibition.
Jakubowski JA; Bourguet N; Boulay-Moine D; Sugidachi A; Yamaguchi S; Barragan P; Zhou C; Moulard M
Thromb Haemost; 2012 Feb; 107(2):388-95. PubMed ID: 22186965
[TBL] [Abstract][Full Text] [Related]
40. Antipsychotic Drugs Inhibit Platelet Aggregation via P2Y 1 and P2Y 12 Receptors.
Wu CC; Tsai FM; Chen ML; Wu S; Lee MC; Tsai TC; Wang LK; Wang CH
Biomed Res Int; 2016; 2016():2532371. PubMed ID: 27069920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
